Skip to main content
Dec 14, 2018

Merck buys animal health company Antelliq for $3.7 billion

Dan Primack
View of the entrance to the Mission Bay office of pharmaceutical company Merck

Photo by Smith Collection/Gado via Getty Images

Merck (NYSE: MRK) agreed to buy Antelliq Group, a French provider of animal identification, tracing and monitoring solutions, from BC Partners for approximately $3.7 billion (including debt assumption).

Why it matters: It seems that the only thing hotter than human health deals in 2018 has been animal health deals, whether it be food (General Mills buying Blue Buffalo), veterinary services (Henry Schein spin-off/merger), diagnostics (Zoetis buying Abaxis), medicine (Elanco IPO) or the sorts of ancillary services that Antelliq provides.

  • Bottom line: "Antelliq’s products, which brought in €360 million euros in sales in the year ended Sept. 30, provide veterinarians, farmers and pet owners with digital technology that monitors animals and helps predict disease in them." — Reuters
Go deeper